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Heart failure is more prevalent among African Americans than in the general population. Metabolomic studies
among African Americans may efficiently identify novel biomarkers of heart failure. We used untargeted methods to
measure 204 stable serum metabolites and evaluated their associations with incident heart failure hospitalization
(n = 276) after a median follow-up of 20 years (1987–2008) by using Cox regression in data from 1,744 African Amer-
icans aged 45–64 years without heart failure at baseline from the Jackson, Mississippi, field center of the Atheroscle-
rosis Risk in Communities (ARIC) Study. After adjustment for established risk factors, we found that 16 metabolites
(6 named with known structural identities and 10 unnamed with unknown structural identities, the latter denoted by
using the format X-12345) were associated with incident heart failure (P < 0.0004 based on a modified Bonferroni
procedure). Of the 6 named metabolites, 4 are involved in amino acid metabolism, 1 (prolylhydroxyproline) is a
dipeptide, and 1 (erythritol) is a sugar alcohol. After additional adjustment for kidney function, 2 metabolites
remained associated with incident heart failure (for metabolite X-11308, hazard ratio = 0.75, 95% confidence inter-
val: 0.65, 0.86; for metabolite X-11787, hazard ratio = 1.23, 95% confidence interval: 1.10, 1.37). Further structural
analysis revealed X-11308 to be a dihydroxy docosatrienoic acid and X-11787 to be an isoform of either hydroxyleu-
cine or hydroxyisoleucine. Our metabolomic analysis revealed novel biomarkers associated with incident heart
failure independent of traditional risk factors.
heart failure; metabolomics; risk factors
Abbreviations: ARIC, Atherosclerosis Risk in Communities; eGFR, estimated glomerular filtration rate; PUFA, polyunsaturated
fatty acid.
Heart failure is a leading cause of morbidity and mortality
and its prevalence continues to rise in the United States, partly
because of a shift in the age distribution of the population
(1, 2). Identification of novel risk factors for heart failure may
reduce the burden on the health-care system and improve qual-
ity of life (1). Several risk factors for heart failure have been
identified, including age, African-American race, male sex,
prevalent coronary heart disease, left ventricular hypertrophy,
diabetes, hypertension, kidney dysfunction, low physical activ-
ity, dyslipidemia, cigarette smoking, and obesity (1, 3–13).
Metabolomic technologies allow for global characteri-
zation of metabolic networks by untargeted quantification of
many low-molecular-weight metabolites present in a biolog-
ical sample (14). Thus, metabolomic analysis may identify
single biomarkers of heart failure or collections ofmetabolites
pointing to dysregulatedmetabolic pathways underlying heart
failure etiology. Although some studies have evaluated meta-
bolomic changes following heart failure onset (15, 16), few
have sought to identify upstream physiological factors that
predict future heart failure. Furthermore, to date, no study
has explored the metabolomic antecedents of heart failure in
African Americans, a race group with the highest rate of hos-
pitalization for heart failure and cardiovascular disease mor-
tality (17). Although socioeconomic status and health care
accessibility likelyplay important roles (18), thephysiological
factors underlying this risk disparity are not well understood.
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Therefore, we evaluated whether baseline metabolomic bio-
markers were associated with incident hospitalized heart failure
independent of established risk factors during approximately
20 years of follow-up in awell-characterized, population-based
sample of African Americans from the Atherosclerosis Risk in
Communities (ARIC) Study.
MATERIALS AND METHODS
Study design and population
The ARIC Study is designed to study the causes and out-
comes of cardiovascular disease in a prospective cohort of
15,792 individuals from 4 communities (Forsyth County,
North Carolina; Jackson, Mississippi; the suburbs of Minne-
apolis, Minnesota; and Washington County, Maryland).
Detailed descriptions of its design, objectives, and procedures
have been published elsewhere (19).Metabolomic profileswere
measured in a subsample of African-American participants,
including 1,977 individuals randomly selected from the Jack-
son, Mississippi, field center who provided consent for genetic
research, provided dietary quality data, and had a stored
fasting (≥8 hours) serum sample at the baseline examination.
For the current analysis, we excluded participants with base-
line prevalent heart failure (n = 97), missing follow-up infor-
mation on incident heart failure (n = 30), or missing values for
the baseline covariates (n = 106). The final sample size for the
results presented here was 1,744.
Assessment of baseline covariates and metabolites
Prevalent coronary heart disease was defined by evidence
of previous myocardial infarction by electrocardiogram at
baseline, history of physician-diagnosed myocardial infarc-
tion, or previous coronary reperfusion procedure (19). Cur-
rent cigarette smoking status, physical activity (continuous
variable) (20), and educational level (6-level ordinal vari-
able) (21) were self-reported. A standardized protocol was
used to measure blood pressure (22). Antihypertensive and
lipid-lowering medication use during the past 2 weeks was
ascertained by inventory. Diabetes was defined as a fasting
serum glucose level ≥126 mg/dL (23) or the use of diabetes
medication. Left ventricular hypertrophy was measured by
electrocardiography according to the Cornell voltage criteria
(24). Estimated glomerular filtration rate (eGFR) was calcu-
lated by using the Chronic Kidney Disease Epidemiology
Collaboration equation (25).
Metabolite profiling of fasting serum samples that had
been stored at −80°C since collection at baseline in 1986–
1987 was completed in June 2010. Detection and quanti-
fication of 602 metabolites were completed by Metabolon,
Inc. (Durham, North Carolina) by using an untargeted, gas
chromatography–mass spectrometry and liquid chromatog-
raphy–mass spectrometry–based metabolomic quantification
protocol (26). This untargeted approach identifies and quan-
tifies named compounds whose chemical identities are known
(n = 361), as well as additional unnamed compounds that do
not currently have chemical standards (n = 241) (27). These
unnamed compounds are tagged beginning with “X” and
followed by numbers (e.g., X-12345). A rigorous assessment
of the metabolomic data was done on the basis of 2 criteria.
First, 44 metabolites were excluded because more than 80%
of the samples had missing values or values below the detec-
tion limit of the technology. Considering the appropriateness
of population-based referencing, we preferred a relatively sta-
ble biomarker with a small intrasubject variance compared
with the between-subject variance (28). Second, 386 metabo-
lites were excluded because the medium-term reliability coef-
ficient based on a comparison of 2 samples collected 4–6
weeks apart from 60 individuals was less than 0.60. Of note,
32 metabolites were excluded because they had more than
80% missing values and reliability coefficients of less than
0.60. Thus, the present report is based on an evaluation of 204
stable metabolites, of which 118 had known and 86 had
unknown structural identities (reliability coefficient ≥0.60;
median reliability coefficient, 0.74). The values of 187 metab-
olites with reliability coefficients of 0.60 or higher and missing/
below-the-detection-limit values of less than 50% were ana-
lyzedas continuousvariables, andmissing/below-the-detection-
limit values were assigned the lowest detected value for that
metabolite in all samples. Seventeenmetabolites with reliability
coefficients of 0.60 or higher and missing/below-the-detection-
limit values between 50% and 80% were analyzed as ordinal
variables with the following levels: 1) missing/below-the-
detection-limit values, 2) detected values below themedian; and
3) detected values at or higher than the median.
Instrument variability was determined by calculating the
median relative standard deviation for the internal standards
that were added to each sample prior to injection into the mass
spectrometers. Overall process variability was determined by
calculating themedian relative standard deviation for all endog-
enous metabolites (i.e., noninstrument standards) present in
100% of the technical replicate samples, which were created
fromahomogeneous pool of humanplasma.Because this study
spanned multiple days, a data normalization step was per-
formed to correct variation resulting from differences in instru-
ment tuning from day to day. Essentially, each compound was
corrected in run-day blocks by registering the medians to equal
1.00 and normalizing each data point proportionately.
Compounds were identified by comparison with an in-
house–generated authentic standard library that includes reten-
tion times, molecular weights, preferred adducts, in-source
fragments, and associated fragmentation spectra of the intact
parent ions. The database allows for rapid and high-confidence
identification of experimentally detected molecules on a multi-
parameter match basis without the need for additional analyses.
Unnamed compounds of interest were subjected to detailed
analysis by mass spectrometry and mass spectrometryn (i.e.,
the accurate monoisotopic mass and fragmentation patterns of
the primary ion, aswell as higher order fragmentations) by using
an Orbitrap Elite instrument (Thermo Fisher Scientific, Inc.,
Waltham, Massachusetts). Resulting empirical formulas were
queried against the ChemSpider database (http://www.chem
spider.com/) search engine for potential structure matches.
Follow-up and outcome events
Individuals were considered to have prevalent heart failure
if they had stage-3 heart failure or “manifest heart failure”
at baseline according to the Gothenburg criteria (29, 30) or
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medication use for heart failure during the last 2 weeks before
baseline (19, 31). In individuals free of prevalent heart
failure, incident heart failure was defined as the first occur-
rence of either a hospitalization that included an Interna-
tional Classification of Diseases, Ninth Revision, discharge
code of 428 (428.0–428.9) in any position or a death certifi-
cate with a code of 428 (heart failure) or International Clas-
sification of Diseases, Tenth Revision, code I50 (heart failure)
in any position (6, 31). Participants who were lost to follow-
up were censored at the date of last contact. Individuals were
followed up for events until death or December 31, 2008.
There were 276 incident heart failure cases during approxi-
mately 20 years of follow-up.
Statistical analysis
Baseline data are presented as means and standard errors
for the continuous variables and as numbers and percentages
for the categorical variables. Baseline characteristics were
compared by using the χ2 test for categorical variables and a
2-sample Student’s t test for continuous variables. Cox pro-
portional hazards regression was used to assess associations
between each metabolite and incident hospitalization for
heart failure. Covariates were selected on the basis of pub-
lished reports (32–34). Four hierarchical models were used.
Model 1 adjusted for unmodifiable factors, including age,
sex, and prevalent coronary heart disease. Model 2 addition-
ally adjusted for the following lifestyle factors: physical
activity, education, and current smoking status. Model 3
additionally adjusted for the following physiological factors:
body mass index (weight (kg)/height (m)2), systolic blood
pressure, antihypertensive medication use, fasting serum glu-
cose levels, prevalent diabetes, ratio of serum total choles-
terol to high-density lipoprotein cholesterol, lipid-lowering
medication use, and left ventricular hypertrophy. Model 4
additionally adjusted for eGFR (25) because kidney dys-
function is a known risk factor for heart failure (35) and may
also reciprocally act on serum metabolite concentrations (i.e.,
kidney function may affect the levels of certain metabolites,
and certainmetabolites, especially the exogenousmetabolites
from medication with nephrotoxicity, may be associated with
altered kidney function) (36, 37). Therefore, kidney function
may be a confounder or a mediator in the association between
the human metabolome and heart failure. Finally, metabo-
lites identified as being associated with heart failure in the
fullest model (model 4) were included together in a single
model to determine whether their associations with heart fail-
ure were mutually independent.
An exploratory analysis that used a compositemetabolomic
scorewas also conducted. Themetabolomic scorewas created
by summing the quartile ranks of metabolites that were asso-
ciated with heart failure in model 3 (the quartile ranks were
reversed for metabolites inversely associated with heart fail-
ure).Theassociationbetween thismetabolomic scoreand inci-
dent heart failure was assessed by adjusting for all covariates
in model 4.
Results of the Cox proportional hazards models are reported
as hazard ratios with corresponding P values. All hazard ratios
were calculated and reported per standard deviation increase
forcontinuousvariables or per1-category change forcategorical
variables. The proportionality assumption was evaluated and
accepted by using the log-log survival curves for categorical
covariates and Schoenfeld’s goodness-of-fit test (38) for con-
tinuous covariates.
A modified stepwise Bonferroni procedure, the Dubey/
Armitage-Parmar algorithm (39), was used to correct for mul-
tiple comparisons. This adjustment takes into account the
full correlation matrix of metabolites and uses the mean cor-
relation among the metabolites in the formula, where the new
α-level for the kth hypothesis for k = 1, 2, . . . , K is read-
justed for each individual metabolite as follows:
αk ¼ 1 ð1 αÞ1=mk ;
where




and rjk is the correlation coefficient between the jth and kth
metabolites. When the average of the correlation coefficients
is 0, this adjustment is identified with the Bonferroni test,
and when it is 1, the adjusted and the unadjusted P values
are the same. When applying this method to each individual
test of association within the current metabolomics data, we
considered a 2-tailed P < 0.0004 to be statistically significant.
All statistical analyses were performed with SAS, version
9.2, software (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Among the 1,744 study participants, 16% (n = 276) devel-
oped hospitalized heart failure during a median follow-up of
20 years (incidence rate: 9.3 per 1,000 person-years). Partic-
ipants who developed heart failure were more likely to be
older, current smokers, obese, hypertensive, diabetic, less
physically active and to have prevalent coronary heart disease
(Table 1). Except for sex, all the baseline risk factors dif-
fered between those who developed heart failure and those
who did not during the follow-up period (P < 0.05).
In models 1, 2, 3, and 4, there were 56, 43, 16, and 2 meta-
bolites, respectively, associated with incident heart failure
(P < 0.0004). As covariates were added, the number of stat-
istically significant metabolites was progressively reduced,
suggesting that lifestyle, physiological factors, and kidney
function are confounders in the association between the
human metabolome and incident heart failure. In model 3,
the 16 significant metabolites included 6 named metabolites
with known structural identities and 10 unnamed metabo-
lites with unknown structural identities. These 16 metabo-
lites were analyzed as continuous variables because of a
high reliability coefficient and a small percentage of missing
values or those below the detection limit. The multivariable
Cox proportional hazards models for these 16 metabolites
are shown in Table 2. Metabolite X-11308 had the largest
effect size and was the only metabolite inversely associated
with heart failure (hazard ratio = 0.75 per standard deviation;
P = 8.34 × 10−5 in model 3). Four of the 6 named metabolites
(N-acetylalanine, p-cresol sulfate, phenylacetylglutamine,
pyroglutamine) are involved in amino acid metabolism; 1
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(prolylhydroxyproline) is a dipeptide; and 1 (erythritol) is a
sugar alcohol. Except for pyroglutamine and prolylhydroxy-
proline, these metabolites were significantly associated with
heart failure in all 3 models. Pyroglutamine was associated
with heart failure only in model 3 with an 11% increase in
the magnitude of its hazard ratio (from 1.17 in model 2 to
1.29 in model 3), a change attributable almost solely to
adjustment for fasting serum glucose level and prevalent dia-
betes. Associations between the baseline established risk
factors and the 16 metabolites that were significantly associ-
ated with incident heart failure in model 3 are shown in the
Web Appendix (available at http://aje.oxfordjournals.org/).
The correlations between each of these 16 metabolites and
eGFR are shown in Table 3. Except for X-11308, heart failure–
related metabolites were consistently negatively associated
with eGFR (i.e., higher concentrations of metabolites were
related to poorer kidney function). The associations of these
16 metabolites with the other established risk factors varied
considerably across metabolites (Web Appendix).
After further adjustment for eGFR (in model 4), only
X-11308 (P = 5.36 × 10−5) and X-11787 (P = 2.84 × 10−4)
remained significantly associated with heart failure risk,
whereas the positive association between pyroglutamine and
heart failure risk was of borderline statistical significance
(P = 0.0006). eGFR itself was associated with incident heart
failure in model 4 (hazard ratio = 0.812, 95% confidence
interval: 0.724, 0.911), showing the expected relationship
between poor kidney function and heart failure risk. Web
Figure 1 illustrates the cumulative hazard of heart failure by
quartiles of these 3 metabolites. When included together in
Table 1. Distribution of Baseline Established Risk Factors by Incident Heart Failure Among 1,744 African Americans in the Jackson, Mississippi,








No. % Mean (SE) No. % Mean (SE) No. % Mean (SE)
Unmodifiable factors
Age, years*** 52.8 (5.7) 52.3 (5.6) 55.3 (5.6)
Male sex 633 36.3 530 36.1 103 37.3
Prevalent coronary heart disease*** 57 3.3 31 2.1 26 9.4
Lifestyle factors
Current smoker*** 498 28.6 397 27.0 101 36.6
Physical activity a, *** 6.6 (1.4) 6.7 (1.4) 6.1 (1.5)
Educational level***
Grade school or 0 years of education 328 18.8 235 16.0 93 33.7
High school but no degree 369 21.2 313 21.3 56 20.3
High school graduate 367 21.1 316 21.5 51 18.5
Vocational school 119 6.8 106 7.2 13 4.7
College 308 17.7 268 18.3 40 14.5
Graduate or professional school 253 14.5 230 15.7 23 8.3
Physiology factors
Body mass indexb, *** 29.5 (6.0) 29.2 (5.8) 31.1 (6.6)
Systolic blood pressure, mm Hg*** 128.1 (21.3) 126.7 (20.4) 135.2 (24.5)
Antihypertensive medication use** 618 35.4 475 32.4 143 51.2
Fasting glucose, mmol/L*** 6.2 (2.5) 5.9 (2.0) 7.6 (4.1)
Prevalent diabetes*** 270 15.5 170 11.6 100 36.2
Serum total cholesterol to high-density
lipoprotein cholesterol ratio***
4.2 (1.5) 4.1 (1.5) 4.5 (1.5)
Lipid-lowering medication use* 17 1.0 11 0.8 6 2.2
Left ventricular hypertrophy*** 83 4.8 50 3.4 33 12.0
eGFR, mL/min/1.73 m2*** 104.5 (18.1) 105.5 (16.9) 99.2 (22.5)
Abbreviations: ARIC, Atherosclerosis Risk in Communities; eGFR, estimated glomerular filtration rate; SE, standard error.
* P < 0.05; **P < 0.01; ***P < 0.001 (P values for the test for difference in each risk factor between the nonincident heart failure group and the
incident heart failure group).
a Physical activity was calculated from a modified Baecke questionnaire on habitual physical activity by integrating the types and intensity of
physical activity via principal components analysis; therefore, there is no unit of measurement.
b Body mass index is weight (kg)/height (m)2.
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model 4, the 3 metabolites, X-11308, X-11787, and pyro-
glutamine, were each independently associated with heart
failure (P = 0.0004, 0.001, and 0.004, respectively). Sensi-
tivity analyses excluding cases during the first 3, 5, and 8
years of follow-up were performed, and X-11308 and X-
11787 were consistently identified as the top 2 metabolites
in each analysis (data not shown).
We further identified with good confidence the general
structures of the 2 unnamed metabolites, X-11308 and X-
11787. The unnamed metabolite, X-11308, has a monoiso-
topic accurate mass of 366.27736 g/mol and an empirical
formula of C22H38O4 with 4 double bonds based on perfect
matches in both mass and isotope pattern. Detailed analyses
of fragmentation pathways revealed it to be consistent with
dihydroxy docosatrienoic acid (22:3), a long-chain polyun-
saturated fatty acid (PUFA). For the other unnamed metabo-
lite, X-11787, the neutral accurate mass was measured as
147.08952 g/mol with an empirical molecular formula of
C6H13NO3 and 1 double bond. Analysis of fragmentation
spectra suggests this unknown metabolite is an isoform of
either hydroxyleucine or hydroxyisoleucine. The metabo-
lomic score created from the 16 metabolites identified in
model 3 ranged from 2 to 48 (mean = 23.84; standard devia-
tion, 8.47). Each higher standard deviation in the metabolo-
mic score was associated with a 38% greater risk of heart
failure in model 4 (hazard ratio = 1.38, 95% confidence inter-
val: 1.18, 1.62; P = 5.36 × 10−5). A histogram of the metab-
olomic score by incident heart failure status is shown in
Figure 1.
To better understand how the identified metabolites fit into
larger metabolomic pathways, we calculated the age- and
sex-adjusted Pearson correlations among all of the metabo-
lites (Web Figure 2A). Strong correlations were observed in
the X-11308 and X-11372 pair (r = 0.66), the X-11308 and
X-11880 pair (r = 0.60), and the pyroglutamine and creatine
pair (r =−0.44). Except in these pairs, the correlations between
the metabolites associated with heart failure and the other
metabolites were weak (metabolite-metabolite r ranged from
−0.14 to 0.36). To illustrate the pairwise correlations among
the identified potential biomarkers of heart failure, we show
Table 2. Adjusted Hazard Ratiosa for Incident Heart Failure in 3 Models in Relationship to 16 Candidate Metabolitesb in Model 3 Among
1,744 African Americans in the Jackson, Mississippi, Field Center of the ARIC Study, 1987–2008
Metabolite
Model 1c Model 2d Model 3e Model 4f









X-11429 1.22* 1.15, 1.29 1.16* 1.09, 1.23 −26.47 1.14* 1.08, 1.21 −10.70 1.10 1.02, 1.18 −29.01
X-11687_200 1.27* 1.20, 1.35 1.24* 1.16, 1.32 −12.33 1.18* 1.10, 1.26 −23.24 1.13 1.03, 1.22 −27.50
Erythritol 1.29* 1.22, 1.35 1.24* 1.18, 1.31 −13.46 1.16* 1.09, 1.23 −32.94 1.10 1.01, 1.20 −32.43
N-Acetylalanine 1.18* 1.11, 1.25 1.16* 1.09, 1.23 −11.88 1.15* 1.08, 1.23 −1.67 1.11 1.02, 1.20 −29.20
X-12096 1.28* 1.21, 1.36 1.22* 1.15, 1.30 −18.93 1.15* 1.08, 1.23 −28.51 1.10 1.01, 1.20 −34.25
X-11787h 1.36* 1.23, 1.51 1.36* 1.23, 1.51 1.30 1.27* 1.14, 1.41 −23.87 1.23* 1.10, 1.37 −13.19
X-11334 1.18* 1.12, 1.25 1.17* 1.11, 1.23 −7.70 1.13* 1.07, 1.19 −22.31 1.09 1.02, 1.16 −30.00
Pyroglutamine 1.20 1.06, 1.36 1.17 1.03, 1.32 −15.26 1.29* 1.15, 1.46 67.14 1.25 1.10, 1.41 −14.52
X-11423 1.22* 1.16, 1.29 1.17* 1.10, 1.23 −23.13 1.13* 1.07, 1.19 −21.98 1.08 1.00, 1.16 −37.32
Phenylacetylglutamine 1.20* 1.13, 1.27 1.18* 1.11, 1.25 −11.57 1.15* 1.08, 1.23 −12.49 1.10 1.01, 1.20 −33.26
X-04499 1.36* 1.22, 1.53 1.31* 1.17, 1.47 −12.66 1.25* 1.12, 1.40 −17.44 1.19 1.06, 1.34 −21.81
X-11308i 0.67* 0.58, 0.78 0.72* 0.63, 0.83 −18.67 0.75* 0.65, 0.87 −11.28 0.75* 0.65, 0.86 1.46
X-11333 1.23* 1.16, 1.30 1.17* 1.10, 1.24 −23.16 1.13* 1.06, 1.20 −20.71 1.08 1.00, 1.17 −39.75
p-Cresol sulfate 1.26* 1.15, 1.38 1.21* 1.11, 1.33 −17.00 1.18* 1.08, 1.28 −14.35 1.11 1.00, 1.23 −36.29
X-11564 1.31* 1.21, 1.42 1.23* 1.14, 1.34 −23.50 1.16* 1.07, 1.26 −29.13 1.09 0.99, 1.20 −40.09
Prolylhydroxyproline 1.24* 1.12, 1.37 1.18 1.07, 1.31 −22.33 1.17* 1.07, 1.27 −7.52 1.11 1.01, 1.22 −31.60
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CI, confidence interval; HR, hazard ratio.
* P < 0.0004.
a Hazard ratios are calculated for 1 standard deviation increase in continuous variables or a transfer from 1 level to another in categorical
variables.
b Unnamed metabolites with unknown structural identities are denoted by using the format X-12345.
c Model 1 is adjusted for unmodifiable factors.
d Model 2 is adjusted for unmodifiable factors and lifestyle factors.
e Model 3 is adjusted for unmodifiable factors, lifestyle factors, and physiology factors.
f Model 4 is adjusted for unmodifiable factors, lifestyle factors, physiology factors, and estimated glomerular filtration rate.
g Change in the β regression coefficient.
h An isoform of either hydroxyleucine or hydroxyisoleucine.
i A dihydroxy docosatrienoic acid.
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the partial metabolite-metabolite correlations of the 16 sig-
nificant metabolites identified in model 3 in Web Figure 2B.
DISCUSSION
By using a mass spectrometry–based metabolite profiling
platform (26), we found that some metabolomic compounds
measured in prospectively collected and stored serum sam-
ples were significantly associated with incident heart failure
in a well-characterized, population-based sample of African
Americans. Associations between 16 metabolites and inci-
dent heart failure were noted after adjustment for estab-
lished risk factors. Each 1–standard deviation increase in a
metabolomic score, consisting of the sum of the quartile ranks
of the 16 metabolites, was associated with a 38% increased
risk of heart failure in the fullest model (95% confidence
interval: 1.18, 1.62). Two metabolites, X-11308 and X-1178,
remained associated and 1 metabolite (pyroglutamine) retained
a borderline significant association with incident heart failure
after adjustment for established heart failure risk factors and
eGFR. The metabolites that were no longer associated after
adjustment for eGFR may be related to incident heart failure
via pathways related to kidney dysfunction. For example, p-
cresol sulfate, a significant predictor in model 3 with adverse
cardiovascular effects (40, 41), is cleared by the kidneys and
was no longer a significant predictor of incident heart failure
after adjustment for eGFR.
Though the exact identification of unknown metabolites
remains a challenge (42), the putative chemical structures
for the 2 unnamed candidate metabolites were identified.
The unnamed metabolite, X-11308, was identified as a dihy-
droxy docosatrienoic acid (22:3), which is a PUFA. Long-
chain PUFAs are considered to be associated with lower
cardiovascular risk, including heart failure (43). PUFAs may
reverse adverse mechanical/electrical remodeling via a mul-
titude of mechanisms, such as improving hemodynamics,
promoting antiinflammatory activation, and increasing car-
diac output. Therefore, PUFAs have hypothesized cardio-
protective effects that subsequently reduce the risk of heart
failure (44). Among the PUFAs, eicosapentaenoic acid, doco-
sahexaenoic acid, and α-linolenic acid are well known for
their benefits to cardiovascular health. The results of this
study suggest that docosatrienoic acid may also be associated
with a lower risk of heart failure. The other unnamed metabo-
lite, X-11787, was identified as an isoform of either hydroxy-
leucine or hydroxyisoleucine. Hydroxyleucines are known
oxidized end products of leucine or hydroperoxyleucines.
This modification is irreversible, making hydroxyleucines
useful in vivo markers of protein oxidation (45). Oxidative
damage to cellular proteins and membranes is an obvious
mechanism through which myocardial oxidative stress impairs
cardiac function, thereby inducing cellular dysfunction or
death through apoptosis and necrosis (46). Oxidation of skele-
tal muscle actin, tropomyosin, and myosin occurs in chronic
heart failure, and it further depresses muscle function and exer-
cise capacity (47). To our knowledge, there are no previous
reports of a possiblemechanism for a cardiac effect of hydroxy-
isoleucine.
Strengths and limitations
Strengths of this study include the use of a well-characterized
African-American cohort with detailed clinical characteriza-
tion. The long period of prospective follow-up enabled us to
show that the circulating metabolomic differences can occur
well before any alteration is detectable in pathophysiology
of heart failure development by standard clinical measures.
Earlier research results (48) suggest that error can occur when
single measurements of serum metabolites are used to cate-
gorize individuals because of high intraindividual variation;
therefore, strict quality standards for the metabolomic data
were applied here to ensure a valid and reliable conclusion.
This study is among the first to evaluate the medium-term
reliability of metabolomic data in human samples from a pro-
spective cohort study although, as a consequence, only about
one-third of the metabolites satisfied our criterion for reliabil-
ity to be included in this analysis. As an exploratory exercise,
we reanalyzed incident heart failure beginning with all 602
metabolites, and the 2 significant metabolites identified in
model 4 remained significant (data not shown). The reliabil-
ity of these 2 metabolites over time and the consistency of
their association with incident heart failure bode well for
Table 3. Associations Between Each of 16 Candidate Metabolitesa
and eGFR Among 1,744 African Americans in the Jackson,






X-11429 −0.389 1.78 × 10−69
X-11687_200 −0.335 8.73 × 10−50
Erythritol −0.426 9.90 × 10−86
N-Acetylalanine −0.387 1.06 × 10−68
X-12096 −0.391 2.68 × 10−70
X-11787c −0.163 5.33 × 10−12
X-11334 −0.294 1.27 × 10−37
Pyroglutamine −0.188 2.27 × 10−15
X-11423 −0.447 2.59 × 10−96
Phenylacetylglutamine −0.329 5.72 × 10−48
X-04499 −0.225 5.31 × 10−22
X-11308d −0.008 0.75
X-11333 −0.380 1.14 × 10−65
p-Cresol sulfate −0.342 5.42 × 10−52
X-11564 −0.361 1.23 × 10−58
Prolylhydroxyproline −0.264 3.09 × 10−30
Abbreviations: ARIC, Atherosclerosis Risk in Communities; eGFR,
estimated glomerular filtration rate.
a Unnamed metabolites with unknown structural identities are
denoted by using the format X-12345.
b Correlation coefficients are calculated with adjustment for age
and sex.
c An isoform of either hydroxyleucine or hydroxyisoleucine.
d X-11308, a dihydroxy docosatrienoic acid, is the only heart
failure–related metabolite that was not significantly associated with
eGFR.
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their potential as applied biomarkers contributing to the body
of knowledge regarding heart failure etiology or predicting
future heart failure. A growing number of studies have used
mass spectrometry as a tool for biomarker discovery, but
these studies have been largely cross-sectional (49, 50), pro-
viding limited information regarding the relationships of
metabolomic biomarkers to the development of future dis-
ease (14). No study, to our knowledge, has tested whether
metabolomic profiling of prospectively collected serum sam-
ples in large cohorts can identify novel biomarkers of future
incident heart failure. The present study identified novel can-
didate metabolites that were associated with future heart
failure by using untargeted metabolite profiling in African
Americans in the ARIC Study over approximately 20 years
of follow-up.
There are many possible extensions to this work. First,
further biological confirmation of the candidate metabolites
(dihydroxy docosatrienoic acid (X-11308) and hydroxyleu-
cine or hydroxyisoleucine (X-11787)) should be performed.
Second, the candidate metabolites of interest from this study
should be measured in an independent replication sample of
AfricanAmericans.Third,geneticfactorsassociatedwithlevels
of these candidate metabolites can be explored, as well as the
genotype-environment interactions as they influence levels of
these metabolites and, ultimately, heart failure. Genome-wide
association studies on these incident heart failure–relatedmetab-
olites will be worthwhile, because they can quantify the asso-
ciation between genome-wide significant single-nucleotide
polymorphisms and incident heart failure and therefore help
clarify the whole genetic pathway of heart failure by integrat-
ing genetics and metabolomics. Finally, metabolomics is an
emerging field, and the degree to which the human serum
metabolome may or may not be stable over several decades of
freezing at−80°C is unknown.Wewould expect, however, that
the degree towhich there is instability in themetabolomewould
not be related to the development of future heart failure.
The degree to which the results presented here are ethni-
cally specific is unknown. The prevalence of heart failure is
higher inAfricanAmericans comparedwith the general popu-
lation (51, 52), and this difference can be partially explained
by a higher prevalence of risk factors, such as hypertension
(53). The factors underlying these disparities are not well
understood. Genetic factors influence the risk of heart failure
(54, 55), and population differences in the frequency and
effects of these genetic factors also likely have a role. To our
knowledge, there are no published large studies comparing
the metabolic profile of African Americans with that of other
populations, and this would be an important area for future
investigations.
Conclusions
From a panel of 204 stable metabolites, 3 potential novel
biomarkers were associated with incident heart failure, inde-
pendent of traditional risk factors. Further investigation is
warrantedto testwhether serummetabolitemeasurementshelp
identify candidates for interventions to reduce heart failure
Figure 1. A histogram of metabolomic score by incident heart failure status among 1,744 African Americans from the Jackson, Mississippi, field
center of the Atherosclerosis Risk in Communities (ARIC) Study, 1987–2008.
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risk and elucidate the biologicalmechanisms bywhich certain
metabolites promote heart failure.
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